• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Astrazeneca COVID-19 vaccine effective against variants found in India

firstwordpharmaJune 23, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

AstraZeneca, citing a study, said its COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, as reported by U.S. News & World Report.

Astrazeneca COVID-19 vaccine effective against variants found in India

The University of Oxford study investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralize the variants.

An analysis by Public Health England (PHE) last week showed that vaccines developed by Pfizer and AstraZeneca offer protection of more than 90% against hospitalization from the Delta variant.

AstraZeneca said the latest results are built on the recent analysis by PHE.

Previous:Memos reveal internal FDA struggle over thorny Alzheimer's drug approval

Next:COVID-19 Vaccine Coverage in U.S. Highest Among ≥65-Year-Olds

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Astrazeneca COVID-19 vaccine effective against variants found in India | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

H7N9 Inactivated Influenza Vaccine-HUALAN BIO

H7N9 Inactivated Influenza Vaccine-HUALAN BIO
Influenza Vaccine tetravalence

Influenza Vaccine tetravalence
Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine

Group A and C Meningococcal+Haemophilus Type B Conjugate Vaccine
Flu Vaccine by Hualan Bio

Flu Vaccine by Hualan Bio
Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)
Hualan's Influenza Vaccine

Hualan's Influenza Vaccine
Quadrivalent Influenza Vaccine Hualan Bio

Quadrivalent Influenza Vaccine Hualan Bio
Polyvalent Pneumococcal Polysaccharide Vaccine

Polyvalent Pneumococcal Polysaccharide Vaccine
2024-2025 trivalent flu vaccine WHO-PQ

2024-2025 trivalent flu vaccine WHO-PQ
Influenza Vaccine(Split Virion),Inactivated of Hualan Bio

Influenza Vaccine(Split Virion),Inactivated of Hualan Bio

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service